New York City has agreed to pay the federal government $70 million to settle claims that it allegedly overbilled Medicaid by improperly approving home care for elderly clients. As part of the settlement, NYC admitted that it reauthorized treatment of a number of patients without having first obtained required assessments from doctors, nurses and social workers. The allegations came to light as the result of a whistleblower, Dr. Gabriel Feldman, who was an independent medical reviewer under contract with NYC. Dr. Feldman filed a lawsuit under the False Claims Act and stands to recover $14.7 million of the settlement.
Archive for November, 2011
GlaxoSmithKline, one of the world’s largest drug manufacturers, settled a number of claims resulting from government investigations including one tied to the sale of diabetes drug, Avandia, which has been associated with increased heart risks, and one related to off-label marketing of other drug products. GlaxoSmithKline contends that as a result of claims such as these, it has revamped its compliance and marketing practices to avoid risks of illegal and improper marketing.
An article authored by Marc S. Raspanti, Esquire and Bryan S. Neft, Esquire and published in The Legal Intelligencer, November 1, 2011.
To read the article see: http://www.falseclaimsact.com/library/files/20111101093225001.pdf